Alkermes/$ALKS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Alkermes
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
- Ticker
- $ALKS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,050
- Headquarters
- Dublin, Ireland
- Website
- www.alkermes.com
Alkermes Metrics
BasicAdvanced
$7.6B
116.78
$0.39
0.26
-
Price and volume
Market cap
$7.6B
Beta
0.26
52-week high
$55.67
52-week low
$27.00
Average daily volume
2.1M
Financial strength
Current ratio
2.3
Quick ratio
1.681
Long term debt to equity
0.816
Total debt to equity
0.87
Interest coverage (TTM)
3.78%
Profitability
EBITDA (TTM)
284.932
Gross margin (TTM)
87.18%
Net profit margin (TTM)
3.97%
Operating margin (TTM)
13.39%
Effective tax rate (TTM)
32.06%
Revenue per employee (TTM)
$810,000
Management effectiveness
Return on assets (TTM)
4.20%
Return on equity (TTM)
3.85%
Valuation
Price to earnings (TTM)
116.785
Price to revenue (TTM)
4.511
Price to book
4.2
Price to tangible book (TTM)
-13.88
Price to free cash flow (TTM)
33.939
Free cash flow yield (TTM)
2.95%
Free cash flow per share (TTM)
1.336
Growth
Revenue change (TTM)
10.79%
Earnings per share change (TTM)
-81.32%
3-year revenue growth (CAGR)
4.48%
10-year revenue growth (CAGR)
9.59%
3-year earnings per share growth (CAGR)
-13.91%
10-year earnings per share growth (CAGR)
-14.35%
What the Analysts think about Alkermes
Analyst ratings (Buy, Hold, Sell) for Alkermes stock.
Analyst projections of the future price of Alkermes stock.
Bulls say / Bears say
LYBALVI has clear demand momentum: Q2 sales rose 12% year on year to $94 million and prescriptions increased 18%, supporting its $380–$400 million 2026 sales outlook. (Alkermes)
The Avadel acquisition added a sizeable sleep-medicine revenue stream: LUMRYZ generated $96.6 million in Q2 sales, with Alkermes forecasting $315–$335 million in 2026 net sales. (Alkermes)
Alixorexton could become a major growth driver: its phase 2 study in narcolepsy type 2 met both primary endpoints, with clinically meaningful improvements in wakefulness and sleepiness and acceptable tolerability. (Alkermes)
The Avadel acquisition has increased financial leverage: at June 30, Alkermes had about $1.48 billion of long-term debt against $692 million of cash and investments, and expects a 2026 GAAP net loss of $95–$115 million. (Alkermes)
ARISTADA sales fell 4.5% year on year to $96.7 million in Q2, despite about $4 million of favourable gross-to-net benefit, raising concern that underlying demand may be weaker than reported. (Alkermes)
Alixorexton faces commercial competition in the emerging orexin market, while early ALKS-7290 data reportedly did not clearly distinguish it from generic solriamfetol, leaving the pipeline’s eventual value uncertain. (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2026.
Alkermes Financial Performance
Revenues and expenses
Alkermes Earnings Performance
Company profitability
Upcoming events
No upcoming events
Alkermes News
AllArticlesVideos
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
Business Wire2 days ago
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Business Wire2 weeks ago
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
Business Wire3 weeks ago
Funds containing Alkermes
AllUSDEURGBP
Fund name | Fund size | $ALKS weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.72% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.72% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.72% |
iShares Ageing Population$AGED | $953M | 0.50% |
iShares Ageing Population£AGES | $953M | 0.50% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.